AVLN — AVALYN PHARMACEUTICALS INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
As of Q2 2026, 94 SEC-registered investment managers reported holding AVLN (AVALYN PHARMACEUTICALS INC) in their latest 13F filings, with a combined reported value of $1.47B across 44.59M shares. Ownership is concentrated: the five largest holders account for 40.8% of reported value and the top ten for 62.1%.
Compared with the prior quarter, 94 opened new positions. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
Major shareholders of AVALYN PHARMACEUTICALS INC (AVLN) include Fidelity Management & Research (FMR), Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, ranked by reported 13F value among the 122 institutional holders on this page.
AVLN is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 60 | 16.84M | $479.36M | +6.3% |
| Q2 2026 | 94 | 44.59M | $1.47B | — |
| Q1 2024 | 1 | 1.00K | $4.72K | -50.0% |
| Q4 2023 | 1 | 2.00K | $8.39K | +0.0% |
| Q3 2023 | 1 | 2.00K | $4.20K | — |
Over the 5 quarters shown, institutional share counts increased 842031% in aggregate (Q3 2023 → Q3 2026); the largest single-quarter swing was Q1 2024 (-50.0%).
Top Institutional Holders (Q3 2026) — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 6.19M | $176.24M | 0.01% | Add | |
| 2.27M | $64.63M | 22.92% | Hold | |
| 1.38M | $39.19M | 0.55% | Hold | |
| 1.33M | $37.75M | 0.00% | Add | |
| 929.82K | $26.49M | 15.08% | Hold | |
| 866.79K | $24.69M | 10.06% | Reduce | |
| 752.82K | $21.45M | 0.00% | Add | |
| 554.00K | $15.78M | 0.00% | New | |
| 471.06K | $13.42M | 0.00% | Add | |
| 378.35K | $10.78M | 1.37% | Add | |
| 331.68K | $9.11M | 0.00% | Hold | |
| 189.25K | $5.39M | 0.00% | Add | |
| 160.00K | $4.56M | 0.01% | Hold | |
| 126.74K | $3.61M | 0.61% | New | |
| 125.80K | $3.58M | 0.00% | Add | |
| 122.93K | $3.50M | 0.00% | Add | |
| 95.56K | $2.72M | 0.00% | New | |
| 98.18K | $2.66M | 0.00% | Add | |
| 54.58K | $1.56M | 0.01% | New | |
| 47.47K | $1.35M | 0.01% | New | |
| 47.12K | $1.34M | 0.00% | New | |
| 44.04K | $1.25M | 0.00% | Add | |
| 32.25K | $918.69K | 0.00% | Add | |
| 31.40K | $894.59K | 0.00% | New | |
| 31.25K | $890.28K | 0.00% | Add |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 25 funds
Q1 2024 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 1.00K | $4.72K | 0.00% | Reduce |
Q4 2023 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 2.00K | $8.39K | 0.00% | Hold |
Q3 2023 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 2.00K | $4.20K | 0.00% | New |
New Positions (Q2 2026)
- Fidelity Management & Research (FMR) 5.84M sh · $192.10M
- Novo Holdings A/S 3.88M sh · $127.84M
- SR ONE CAPITAL MANAGEMENT, LP 3.31M sh · $108.92M
- PERCEPTIVE ADVISORS LLC 2.68M sh · $88.07M
- MONTANOVA CAPITAL, LLC 2.50M sh · $82.40M
- NVP Associates, LLC 2.27M sh · $74.68M
- WELLINGTON MANAGEMENT GROUP LLP 2.20M sh · $72.49M
- PRICE T ROWE ASSOCIATES INC /MD/ 1.74M sh · $57.12M
- Catalio Capital Management, LP 1.68M sh · $55.17M
- T. Rowe Price Investment Management, Inc. 1.60M sh · $52.76M
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M sh · $45.28M
- Bellevue Group AG 1.35M sh · $44.44M
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|
| Fidelity Management & Research (FMR) | 6.19M | 5.84M | — | — | — |
| NVP Associates, LLC | 2.27M | 2.27M | — | — | — |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.38M | 1.38M | — | — | — |
| BlackRock Inc | 1.33M | 977.26K | — | — | — |
| Andera Partners | 929.82K | 929.82K | — | — | — |
| Pivotal bioVenture Partners Investment Advisor LLC | 866.79K | 966.79K | — | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 752.82K | 739.77K | — | — | — |
| STATE STREET CORP | 554.00K | — | — | — | — |
| Geode Capital Management | 471.06K | 434.65K | — | — | — |
| SILVERARC CAPITAL MANAGEMENT, LLC | 378.35K | 330.49K | — | — | — |
| Franklin Resources | 331.68K | 331.68K | — | — | — |
| UBS Group AG | 189.25K | 12.30K | — | — | — |
| FEDERATED HERMES, INC. | 160.00K | 160.00K | — | — | — |
| Jones Hill Capital LP | 126.74K | — | — | — | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 125.80K | 117.34K | — | — | — |
| VANGUARD FIDUCIARY TRUST CO | 122.93K | 116.76K | — | — | — |
| Manulife Financial | 95.56K | — | — | — | — |
| TD ASSET MANAGEMENT INC | 98.18K | 94.64K | — | — | — |
| Walleye Capital LLC | 54.58K | — | — | — | — |
| Quadrature Capital Ltd | 47.47K | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold AVLN?
As of 2026-Q2, 94 institutional funds reported holding AVLN (AVALYN PHARMACEUTICALS INC) in SEC 13F filings, with a combined reported value of $1.47B.
How many shares of AVLN do institutions own?
13F filers reported 44.59M shares of AVLN, worth $1.47B in aggregate at the end of 2026-Q2.
Is institutional ownership of AVLN rising or falling?
No prior-quarter baseline is available for a directional read.
Who are the top institutional holders of AVLN?
The largest 13F holders are Fidelity Management & Research (FMR), Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, MONTANOVA CAPITAL, LLC; the top 25 are ranked at the top of this page.
Who are the major shareholders of AVALYN PHARMACEUTICALS INC?
The major shareholders of AVALYN PHARMACEUTICALS INC (AVLN) by reported 13F value are Fidelity Management & Research (FMR), Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, MONTANOVA CAPITAL, LLC, among 122 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.